Skip to main content
$2.28 -0.10 (-4.20%) At close · Aug 5
Market Cap
$217.07M
Shares
94.58M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.28 Open$2.35 Day$2.26–2.37 52W$1.30–3.24 Avg vol 30d260K Short int3.0M · 3.2% float · 11.2d Short vol27% Last earningsAug 3, 2026 DataJan 2020–Aug 2026

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.46
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg +1%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 51%
mid-range
Momentum
relative strength
Strong
1-month return −5%
trailing
6-month return +33%
trailing
YTD return +49%
this year
Relative strength +22%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
25 of 79 funds reported for Jun 30 · net -79.2K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.20% of float · ▲ +8.2% MoM · 11.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
79 holders — near 3-yr high, broad support
Squeeze score 74
high risk · 0–100
Fundamentals
Excellent
Revenue growth +161%
Y/Y
Gross margin 87%
expanding
EPS growth +338%
Y/Y
Free cash flow $31.3M
Balance sheet $90.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −37%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
+1% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
51% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
25 of 79 funds reported for Jun 30 · net -79.2K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.20% of float · ▲ +8.2% MoM · 11.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
79 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1 Now $2 · 51% 52-wk high $3
vs 200-day avg +10% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CGEN
Compugen Ltd
this stock
$217.07M +49.0% +346.1% 3.2%
ONC
BeOne Medicines Ltd.
$484.13B +7.8% +22179.2% 744.4 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$119.47B +6.9% +46.2% 27.5 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$79.13B -0.2% +20.8% 19.0 3.4%
ARGX
Argenx SE
$54.30B +3.2% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
78
% held
15.1%
Reported
25 of 79
Top holder
SILVERARC CAPITAL MANAGEM…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
3.0M
Days to cover
11.2d
Change
+229.2K sh
View
Short Volume
Short vol %
27%
As of
Aug 5, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$2.8K
As of
Jul 10, 2026
View
Off-Exchange
Off-exchange %
41.5%
Week of
Jun 29, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$72.8M
Net income (FY)
$35.3M
EPS diluted
$0.38
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 3, 2026
This year
8
View
Proposed Sales
Value
$14.6K
Shares
5.0K
Filed
Apr 27, 2026
View
Exempt Offerings
Offering
$20.0M
Filed
Nov 22, 2021
View
Earnings & Events
Earnings Calls
Last call
Aug 3, 2026
View
Investor Relations
Latest news
Compugen Reports Second Quarter 2…
Published
Aug 3, 2026
View

Performance

5D 20D 120D MTD YTD
CGEN +1.8% -5.4% +33.3% -3.0% +49.0%
SPY +5.5% +3.3% +11.3% +3.1% +12.9%
vs SPY -3.7% -8.7% +22.1% -6.0% +36.1%
Key facts CIK 1119774 CUSIP M25722105 13F (30d) 25 filings 21 filers Visit website Investor relations